---
schema_version: "secwatch.filing_event.v1"
accession: "0000886163-25-000047"
form_type: "8-K"
ticker: "LGND"
cik: "0000886163"
company_name: "LIGAND PHARMACEUTICALS INC"
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T18:43:45.136400+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ligand Q2 royalties up 57% to $36.4M; raises FY2025 guidance to $200-225M revenue and $6.70-7.00 adj. EPS

## Summary
- Q2 revenue $47.6M (+15% YoY); royalties $36.4M (+57%) driven by Qarziba and Filspari.
- GAAP net income $4.8M ($0.24 diluted) vs loss $51.9M in Q2 2024; core adj. EPS $1.60 vs $1.40.
- FY2025 guidance raised: revenue $200-225M (prev $180-200M), adj. EPS $6.70-7.00 (prev $6.00-6.25).
- Pelthos merger closed; Zelsuvmi launched July 10; Ligand earned $5M milestone and 13% royalty.
- Merck acquiring Verona for ~$10B; Ligand holds 3% royalty on Ohtuvayre (COPD).

## SEC filing metadata
- accession: 0000886163-25-000047
- form_type: 8-K
- ticker: LGND
- cik: 0000886163
- company_name: LIGAND PHARMACEUTICALS INC
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886163/000088616325000047/0000886163-25-000047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886163/000088616325000047/lgnd-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000886163-25-000047
- JSON: https://secwatch.observer/filing/0000886163-25-000047.json
- Plain text: https://secwatch.observer/filing/0000886163-25-000047.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.